ERBB2 and breast cancer: However, two HER2-directed antibody−drug conjugates (ADCs) with the chemotherapeutics trastuzumab deruxtecan (T-DXd) and trastuzumab duocarmazine (SYD985) have shown very promising therapeutic activity in patients with HER2-low-positive BC (8–10).